Evidence map›Paper›PMID 28317082›Full record

ReviewCurrent hematologic malignancy reports2017

Current Review on High-Risk Multiple Myeloma.

Henry S H Chan, Christine I Chen, Donna E Reece

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current hematologic malignancy reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Prognostic significance ofJournal of Cancer · 2021
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Henry S H ChanPrincess Margaret Cancer Centre, 610 University Ave, Toronto, ON, M5G 2M9, Canada.
Christine I ChenPrincess Margaret Cancer Centre, 610 University Ave, Toronto, ON, M5G 2M9, Canada.
Donna E ReecePrincess Margaret Cancer Centre, 610 University Ave, Toronto, ON, M5G 2M9, Canada. Donna.Reece@uhn.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewNew risk stratification systems and treatment strategies have been introduced in recent years. We aim to provide an overview of these recent changes and summarise these data in a concise article that would be useful for clinicians. RECENT

findingsApart from clinical stage, disease genetics are now recognised as important prognostic risk factors, and various new cytogenetic changes with negative prognostic impact have been identified. New technologies such as minimal residual disease detection are also playing an important role in prognostic assessment. Recent introduction of combination therapy with proteasome inhibitors and immunomodulatory drugs is showing promising results in high-risk patients and may partially abrogate the negative impact associated with some of the adverse risk factors. Recent advance has improved our understanding of high-risk multiple myeloma, and new therapeutic agents are now coming through the pipeline for this patient group with once dismal outcome.

Indexed as

Age FactorsCombined Modality TherapyComorbidityDisease ManagementDisease ProgressionGenetic Predisposition to DiseaseGenetic TestingHumansMultiple MyelomaNeoplasm StagingPrognosisRecurrenceRisk AssessmentRisk FactorsTreatment Outcomedel(17p)High riskMultiple myelomaNovel agentst(4;14)

Identifiers

PMID28317082

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.